Medication info
Olomax Tablet 40/5/5 mg (Olmesartan Medoxomil, Amlodipine, Rosuvastatin)

Olomax Tablet 40/5/5 mg (Olmesartan Medoxomil, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.95mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202001166 · Approved 2020.02.19 · Insurance code 641607220

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine should be taken once daily as 1 tablet with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine and rosuvastatin concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience. Olmesartan medoxomil/amlodipine combination Before administering this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil or amlodipine). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 40/10 mg. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. (olmesartan medoxomil/amlodipine) - 20/5 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg or amlodipine 5 mg monotherapy. - 40/5 mg: For patients whose blood pressure is not adequately controlled with 20/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with 40/5 mg. Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See “Do not administer to the following patients” under Precautions for Use.) Older adults: In general, start at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored more closely and more frequently. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose for adults is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients.

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary heart disease.
View approved original text

This medication is used for patients who need to take a combination of Olmesartan Medoxomil/Amlodipine and Rosuvastatin. The Olmesartan Medoxomil/Amlodipine combination helps control essential hypertension that is difficult to manage with monotherapy. Rosuvastatin primarily acts as an adjunct to dietary therapy in patients with hypercholesterolemia and mixed hyperlipidemia, lowering cholesterol levels in those with hypercholesterolemia and delaying the progression of atherosclerosis. Furthermore, it is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization in high-risk cardiovascular patients. Therefore, this medication is effective for the management of hypertension and hyperlipidemia, as well as for the prevention of cardiovascular diseases.

How to take

Adult dose

This medicine should be taken once daily as 1 tablet with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine and rosuvastatin concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience. Olmesartan medoxomil/amlodipine combination Before administering this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil or amlodipine). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 40/10 mg. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. (olmesartan medoxomil/amlodipine) - 20/5 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg or amlodipine 5 mg monotherapy. - 40/5 mg: For patients whose blood pressure is not adequately controlled with 20/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with 40/5 mg. Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See “Do not administer to the following patients” under Precautions for Use.) Older adults: In general, start at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored more closely and more frequently. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose for adults is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. Older adults: No dose adjustment is necessary. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the 2nd and 3rd trimesters of pregnancy, therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used by individuals who are allergic to the active ingredients or similar components, women who are pregnant or breastfeeding, or fertile women not using adequate contraception. Patients with severe liver or kidney impairment, specific blood disorders, or severe heart disease should consult a physician before using this medication, as it may pose risks. Caution is needed for patients with hypotension due to insufficient body fluid or salt, as blood pressure may drop too low upon initial dosing. The Amlodipine in this medication causes blood vessel dilation to lower blood pressure, and should be used cautiously in patients with heart valve disease. Patients with heart disease or heart failure may experience exacerbation of symptoms, so they should follow a physician's instructions. Patients with decreased kidney function may see further deterioration of kidney function after taking this medication, necessitating regular blood tests and monitoring of their condition. Patients with reduced liver function may require dosage adjustments due to slower metabolism of this medication. There is a risk of increased potassium levels in the blood while taking this medication, so regular testing is needed, especially for individuals with heart or kidney disease. The Rosuvastatin component can cause muscle pain or myopathy, and in rare cases, serious muscle breakdown (rhabdomyolysis) may occur, necessitating prompt reporting of any muscle-related symptoms to a doctor. This medication contains lactose and should not be taken by patients with lactose intolerance. Caution is warranted when taking potassium-sparing diuretics or potassium supplements in conjunction with this medication, as blood potassium levels can become dangerously high. The use of non-steroidal anti-inflammatory drugs (NSAIDs) may worsen kidney function, so caution should be exercised when using pain relievers while on this medication. Taking this medication with grapefruit juice may increase the blood concentration of Amlodipine, increasing the risk of side effects, so it is advisable to avoid this combination. Regular liver function tests and muscle-related tests during the course of this medication are recommended for safety. If severe rashes, itching, swelling, or other symptoms occur after taking this medication, it should be stopped immediately and a doctor should be consulted.

Side effects

Palpitations, abdominal pain, vomiting, weakness, peripheral edema, bacterial pneumonia, subarachnoid hemorrhage, increased ALT, increased AST, hypoglycemia, dizziness, headache, hematuria, allergic rhinitis, cough, wet cough, rash, arterial embolism, drug hypersensitivity reaction, hyperkalemia, decreased libido, orthostatic hypotension, drowsiness, paresthesia, diminished sensation, syncope, vertigo, chest palpitations, tachycardia, hypotension, orthostatic hypotension, dyspnea, indigestion, diarrhea, constipation, dry mouth, urticaria, muscle tension, limb pain, low back pain, erectile dysfunction, edema, depression edema, fatigue, facial edema, decreased serum potassium, increased serum creatinine, increased uric acid, increased gamma-glutamyl transferase, decreased hemoglobin, decreased hematocrit, multiple organ failure syndrome, viral pneumonia, benign neoplasm, malignant neoplasm, neoplasm of unspecified origin, adrenal adenoma, sinus tachycardia, oropharyngeal discomfort, weakness, angioedema, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, hyperkalemia, flushing, fatigue, edema, chest palpitations, dizziness, headache, drowsiness, gynecomastia, jaundice, increased liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, myalgia, myopathy, immune-mediated necrotizing myopathy, muscle rupture, arthralgia, lupus-like syndrome, immune-mediated necrotizing myopathy, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, cough, dyspnea, depression, sleep disturbances, insomnia, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, cognitive impairment, decreased memory, forgetfulness, amnesic syndrome, memory disorder, confusion, severe muscle weakness, ocular myasthenia, headache, chest pain, myalgia, constipation, increased AST, joint pain, numbness, sensory disturbances, chest discomfort, loss of appetite, abdominal bloating, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, avoid extremes of temperature, storing it in a location between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.